Humoral immune response after SARS-CoV-2 vaccination in cladribine-treated multiple sclerosis patients
-
Published:2024-01
Issue:
Volume:16
Page:100445
-
ISSN:2590-1362
-
Container-title:Vaccine: X
-
language:en
-
Short-container-title:Vaccine: X
Author:
Mimpen M.,
Kreiter D.ORCID,
Kempkens T.,
Knippenberg S.,
Hupperts R.,
Gerlach O.
Reference23 articles.
1. SARS-CoV-2 variants, vaccines, and host immunity;Mistry;Front Immunol,2021
2. Real-time assessment of COVID-19 prevalence among multiple sclerosis patients: a multicenter European study;Dalla Costa;Neurol Sci,2020
3. Clinical characteristics and outcomes in patients with coronavirus disease 2019 and multiple sclerosis;Louapre;JAMA Neurol,2020
4. Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional study;Achiron;J Neuroimmunol,2021
5. Achiron A, Mandel M, Dreyer-Alster S, Harari G, Magalashvili D, Sonis P, et al. Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies. Ther Adv Neurol Disord. 2021;14:17562864211012835.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献